Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Radiation sensitizing agents for hypoxic cells: past, present and future]

E Lartigau1

  • 1Département de radiothérapie, institut Gustave-Roussy, Villejuif, France.

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|January 29, 1999
PubMed
Summary

Hypoxic tumor cells resist radiation therapy. New bioreductive drugs combined with radiotherapy show promise in sensitizing these resistant tumors, improving treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Stereotactic body radiation therapy for primary kidney cancer].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

[Five-fraction radiotherapy for breast cancer].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

[Braindrive: Who can drive among patients undergoing brain radiation therapy?]

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

[The role of radiotherapy to the primary tumor and metastases in patients with oligometastatic prostate cancer].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2021
Same author

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.

ESMO open·2021
Same author

[Place and modalities of postoperative radiotherapy in the management of cerebral metastases].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2020

Area of Science:

  • Oncology
  • Radiation Biology
  • Medical Physics

Context:

  • Hypoxic cells are prevalent in tumors and confer resistance to ionizing radiation.
  • The oxygen enhancement ratio (OER) quantifies oxygen's role in radiosensitivity.
  • Tumor partial pressure of oxygen (pO2) is often low (< 10 mmHg) across various cancer types.

Purpose:

  • To review clinical results of radiosensitizing chemical agents used in combination with radiotherapy.
  • To explore novel strategies for overcoming radioresistance in hypoxic tumors.

Summary:

  • Historically, imidazole-based radiosensitizers yielded negative clinical results.
  • Emerging strategies focus on combining bioreductive drugs with radiotherapy to target hypoxic tumor cells.
  • This article details clinical outcomes achieved with these new radiosensitizing chemical agents.

Related Experiment Videos

Impact:

  • Advances in overcoming tumor radioresistance through targeted chemical sensitization.
  • Potential for improved radiotherapy efficacy in hypoxic tumors.
  • Highlights the clinical translation of novel radiosensitizing agents.